Research programme: paclitaxel inhalation - Ventaira
Latest Information Update: 15 Jan 2022
At a glance
- Originator Ventaira Pharmaceuticals
- Developer National Cancer Institute (USA); Ventaira Pharmaceuticals
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 29 Oct 2007 Ventaira Pharmaceuticals has been acquired and merged into Battelle
- 08 Jan 2004 BattellePharma is now called Ventaira Pharmaceuticals
- 24 May 2002 Battelle Pulmonary Therapeutics is now called BattellePharma